image
Healthcare - Biotechnology - NASDAQ - IL
$ 1.825
0.829 %
$ 4.12 M
Market Cap
-0.28
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one GLMD stock under the worst case scenario is HIDDEN Compared to the current market price of 1.82 USD, Galmed Pharmaceuticals Ltd. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one GLMD stock under the base case scenario is HIDDEN Compared to the current market price of 1.82 USD, Galmed Pharmaceuticals Ltd. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one GLMD stock under the best case scenario is HIDDEN Compared to the current market price of 1.82 USD, Galmed Pharmaceuticals Ltd. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart GLMD

image
$3.0$3.0$2.8$2.8$2.6$2.6$2.4$2.4$2.2$2.2$2.0$2.0$1.8$1.8$1.6$1.6$1.4$1.4$1.2$1.2$1.0$1.015 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
0 REVENUE
0.00%
-6.28 M OPERATING INCOME
-83.80%
-7.52 M NET INCOME
-8.75%
-5.88 M OPERATING CASH FLOW
4.19%
-1.11 M INVESTING CASH FLOW
-138.88%
8.79 M FINANCING CASH FLOW
42.05%
0 REVENUE
0.00%
-1.26 M OPERATING INCOME
19.23%
-1.1 M NET INCOME
65.60%
-1.17 M OPERATING CASH FLOW
40.73%
-231 K INVESTING CASH FLOW
93.49%
1.51 M FINANCING CASH FLOW
237.95%
Balance Sheet Galmed Pharmaceuticals Ltd.
image
Current Assets 16.1 M
Cash & Short-Term Investments 15.3 M
Receivables 209 K
Other Current Assets 584 K
Non-Current Assets 2.38 M
Long-Term Investments 2.12 M
PP&E 0
Other Non-Current Assets 257 K
82.87 %3.16 %11.45 %Total Assets$18.5m
Current Liabilities 2.17 M
Accounts Payable 1.31 M
Short-Term Debt 0
Other Current Liabilities 865 K
Non-Current Liabilities 0
Long-Term Debt 0
Other Non-Current Liabilities 0
60.19 %39.81 %Total Liabilities$2.2m
EFFICIENCY
Earnings Waterfall Galmed Pharmaceuticals Ltd.
image
Revenue 0
Cost Of Revenue 83 K
Gross Profit -83 K
Operating Expenses -6.28 M
Operating Income -6.28 M
Other Expenses 1.24 M
Net Income -7.52 M
8m8m6m6m4m4m2m2m00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)0(83k)(83k)6m(6m)(1m)(8m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-46.04% ROE
-46.04%
-40.63% ROA
-40.63%
-38.45% ROIC
-38.45%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Galmed Pharmaceuticals Ltd.
image
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -7.52 M
Depreciation & Amortization 83 K
Capital Expenditures 0
Stock-Based Compensation 531 K
Change in Working Capital -728 K
Others 1.79 M
Free Cash Flow -5.88 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Galmed Pharmaceuticals Ltd.
image
GLMD has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 5
6. Ownership
Insider Ownership Galmed Pharmaceuticals Ltd.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH Biomarker analysis from Phase 3 ARMOR study reveals significant reduction in inflammation, cardiac stress, and atherosclerotic drivers, unlocking potential new commercial and clinical pathways. Validated decrease in ANP (Atrial Natriuretic Peptide), a key clinical marker for heart failure, highlights expansion potential into broader cardiometabolic markets. prnewswire.com - 1 month ago
Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update TEL AVIV, Israel , May 22, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological indications, reports financial results for the three months ended March 31, 2025 and recent developments. prnewswire.com - 1 month ago
Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models Results from studies at Virginia Commonwealth University (VCU) show that an Aramchol and Bayer's Regorafenib drug combination significantly reduced hepatic tumor growth in mice models. The cell killing effect in-vitro and in-vivo was due to increased autophagy and death receptor signaling. prnewswire.com - 2 months ago
Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation The proprietary Self-Emulsifying Drug Delivery System (SEDDS) formulation in form of orally dispersible films allows absorption of sublingually administrated peptides such as GLP-1 (Semaglutide, Liraglutide etc.). The new formulation is expected to offer alternatives to both approved injectable semaglutide (Ozempic© and Wegovy©) and oral form (Rybelsus©), providing a non-invasive route that allows the medication to enter the bloodstream through the oral mucous membranes. prnewswire.com - 2 months ago
Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers Galmed Pharmaceuticals (Nasdaq: GLMD) enters into a Sponsored Project Agreement with Virginia Commonwealth University (VCU) to evaluate Aramchol's effect on overcoming drug resistance in gastrointestinal (GI) cancers. Aramchol, a first-in-class SCD1 inhibitor, will be studied in combination with standard therapies for advanced colorectal and liver cancers, aiming to reverse treatment resistance and improve outcomes in these high-mortality cancers. prnewswire.com - 2 months ago
Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor Analysis of blood samples from patients treated with Aramchol in ARMOR (Ph3 MASH Study) provides new and important insights into the biochemical and physiological effects of the drug. The pharmacodynamic signature associated with Aramchol treatment revealed a decrease in markers of chronic systemic inflammation, oxidative and cardiac stress, and atherosclerotic plaque pathogenesis. prnewswire.com - 2 months ago
Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor – AM-001 Study represents a pivotal milestone in Galmed's transition to Aramchol Meglumine, an improved formulation of its lead compound in advanced clinical development  – Aramchol Meglumine, a New Chemical Entity (NCE) protected by patents until 2035, is being developed both as a standalone agent and in novel drug combinations for multiple indications influenced by fatty acid metabolism  – Initial findings suggest that the new Aramchol Meglumine formulation offers higher bioavailability than Aramchol free acid and that a once-daily, oral 200 mg dose is likely to be optimal for future trials, supporting improved patient compliance and potentially lowering manufacturing costs TEL AVIV, Israel , April 10, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic, and gastrointestinal oncology indications, today announced positive preliminary results from Part 1 of the Ph1 Bioavailability AM-001 Study of Aramchol Meglumine. prnewswire.com - 2 months ago
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024 TEL AVIV, Israel , April 2, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ('Galmed' or the 'Company'), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic diseases and GI oncological indications, today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2024, with the U.S. Securities and Exchange Commission (the 'SEC'). prnewswire.com - 3 months ago
Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy TEL AVIV, Israel , March 20, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic diseases and GI oncological indications, today announced the grant of a new patent related to its lead compound, Aramchol. prnewswire.com - 3 months ago
Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology The paper re-iterates the significant anti-fibrotic effect of Aramchol 300mg BID in patients with metabolic dysfunction associated steatohepatitis (MASH) Data is confirmed using 3 objective measurements; NASH CRN, paired ranked reading, and Artificial Intelligence (AI) quantitative digital analysis Continuous histological fibrosis scores generated in antifibrotic trials by digital pathology images analysis (DIA) quantify antifibrotic effects with greater sensitivity and larger dynamic range than Conventional Pathology TEL AVIV, Israel , Sept. 25, 2024 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. prnewswire.com - 9 months ago
Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases Aramchol is the most clinically advanced, first-in-class, Stearoyl-CoA desaturase1 (SCD1) oral inhibitor, demonstrating in Ph2 and Ph3 (open label part) an excellent safety profile with metabolic and anti-fibrotic effects. Galmed raised an aggregate of $7.5 million in warrant exercises and drawdowns on its recently adopted equity line TEL AVIV, Israel , Sept. prnewswire.com - 9 months ago
Galmed Pharma Surges 400%: What's Behind the Explosion? Galmed Pharmaceuticals NASDAQ: GLMD, a little-known biotech stock, has become the center of attention as its shares have skyrocketed close to 400%. By 2 pm, the stock had traded over 80 million shares, a monumental leap from its average daily volume of just 75,000. marketbeat.com - 9 months ago
8. Profile Summary

Galmed Pharmaceuticals Ltd. GLMD

image
COUNTRY IL
INDUSTRY Biotechnology
MARKET CAP $ 4.12 M
Dividend Yield 0.00%
Description Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.
Contact 16 Tiomkin Street, Ramat Gan, 6578317 https://www.galmedpharma.com
IPO Date March 13, 2014
Employees 3
Officers Mr. Allen Baharaff Co-Founder, President, Chief Executive Officer & Chairman Dr. Tali Gorfine Medical Consultant Mr. Doron Cohen Chief Financial Officer Dr. Liat Hayardeny MBA, Ph.D. Chief Scientific Officer Mr. Yohai Stenzler CPA Chief Accounting Officer Mr. Guy Nehemya Chief Operating Officer & Data Protection Officer